Biogen Inc. (NASDAQ:BIIB) EVP Adriana Karaboutis sold 380 shares of the business’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $313.00, for a total value of $118,940.00. Following the transaction, the executive vice president now owns 7,172 shares in the company, valued at $2,244,836. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Adriana Karaboutis also recently made the following trade(s):

  • On Tuesday, October 4th, Adriana Karaboutis sold 262 shares of Biogen stock. The shares were sold at an average price of $311.94, for a total value of $81,728.28.

Shares of Biogen Inc. (NASDAQ:BIIB) opened at 309.70 on Thursday. The company has a 50-day moving average of $308.94 and a 200 day moving average of $279.14. Biogen Inc. has a 52 week low of $223.02 and a 52 week high of $333.65. The firm has a market capitalization of $67.86 billion, a P/E ratio of 18.09 and a beta of 0.95.

Biogen (NASDAQ:BIIB) last posted its earnings results on Thursday, July 21st. The biotechnology company reported $5.21 EPS for the quarter, topping the consensus estimate of $4.69 by $0.52. The company earned $2.89 billion during the quarter, compared to the consensus estimate of $2.79 billion. Biogen had a net margin of 33.97% and a return on equity of 40.59%. The firm’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the previous year, the firm posted $4.22 earnings per share. Equities research analysts anticipate that Biogen Inc. will post $20.10 earnings per share for the current year.

Insider Buying and Selling by Quarter for Biogen (NASDAQ:BIIB)

A number of research firms have weighed in on BIIB. Piper Jaffray Cos. reaffirmed a “neutral” rating on shares of Biogen in a report on Wednesday, August 3rd. Morgan Stanley lifted their price objective on Biogen from $383.00 to $385.00 and gave the company an “overweight” rating in a report on Thursday, July 21st. Jefferies Group reaffirmed a “buy” rating and set a $317.00 price objective on shares of Biogen in a report on Wednesday, July 13th. Credit Suisse Group AG reaffirmed a “hold” rating and set a $312.00 price objective on shares of Biogen in a report on Friday, July 22nd. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $287.00 price objective on shares of Biogen in a report on Sunday, July 24th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $347.34.

Several large investors have recently bought and sold shares of the company. Primecap Management Co. CA increased its stake in Biogen by 2.8% in the first quarter. Primecap Management Co. CA now owns 16,246,726 shares of the biotechnology company’s stock valued at $4,229,348,000 after buying an additional 436,101 shares during the last quarter. Vanguard Group Inc. increased its stake in Biogen by 1.4% in the second quarter. Vanguard Group Inc. now owns 13,544,616 shares of the biotechnology company’s stock valued at $3,275,359,000 after buying an additional 182,714 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in Biogen by 0.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 5,816,485 shares of the biotechnology company’s stock valued at $1,406,542,000 after buying an additional 50,433 shares during the last quarter. BlackRock Fund Advisors increased its stake in Biogen by 1.5% in the second quarter. BlackRock Fund Advisors now owns 4,843,447 shares of the biotechnology company’s stock valued at $1,171,242,000 after buying an additional 71,709 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in Biogen by 0.7% in the second quarter. Alliancebernstein L.P. now owns 3,184,239 shares of the biotechnology company’s stock valued at $770,013,000 after buying an additional 21,307 shares during the last quarter. 86.21% of the stock is owned by institutional investors.

About Biogen

Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.

5 Day Chart for NASDAQ:BIIB

Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.